Clinical Trials

29 results for Bladder Cancer

Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

  • Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01050504
View Trial

Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

  • Condition: Invasive Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Radiation: Radiotherapy
  • Study ID: NCT02560636
View Trial

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)

  • Condition: Cholangiocarcinoma, Gall Bladder Carcinoma
  • Intervention: Drug: Gemcitabine, Drug: Cisplatin, Other: Observation
  • Study ID: NCT02170090
View Trial

Prospective Randomized Trial of Adjuvant Radiotherapy Following Surgery and Chemotherapy in Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder

  • Condition: Bladder Cancer, Urothelial Carcinoma Bladder
  • Intervention: Radiation: Adjuvant RT
  • Study ID: NCT02951325
View Trial

Lymphadenectomy in Urothelial Carcinoma in the Renal Pelvis and Ureter

  • Condition: Ureteral Neoplasms [C12.758.820.875]
  • Intervention: Procedure: Lymphadenectomy in conjugation with nephroureterectomy, Procedure: Nephroureterectomy without lymphadenectomy
  • Study ID: NCT02607709
View Trial

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney

  • Condition: Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer
  • Study ID: NCT00872495
View Trial

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab
  • Study ID: NCT03171025
View Trial

A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With BCG

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Durvalumab, Drug: Vicinium
  • Study ID: NCT03258593
View Trial

A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab, Drug: Ipilimumab, Procedure: Radical cystectomy
  • Study ID: NCT03520491
View Trial

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

  • Condition: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
  • Intervention: Drug: Gemcitabine Hydrochloride, Drug: Cisplatin, Biological: Pegfilgrastim, Procedure: Conventional Surgery, Procedure: Radical Cystectomy, Other: Chemoradiotherapy
  • Study ID: NCT03609216
View Trial

A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma

  • Condition: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
  • Intervention: Drug: Sitravatinib, Drug: Nivolumab
  • Study ID: NCT03606174
View Trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

  • Condition: Metastatic Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Cabozantinib, Drug: Pembrolizumab
  • Study ID: NCT03534804
View Trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

  • Condition: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
  • Intervention: Drug: Atezolizumab, Drug: Cisplatin, Drug: Fluorouracil, Drug: Gemcitabine, Drug: Mitomycin, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Other: Survey Administration
  • Study ID: NCT03775265
View Trial

Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Celecoxib, Drug: Gemcitabine, Drug: Cisplatin
  • Study ID: NCT02885974
View Trial

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle-

  • Condition: Bladder Cancer, Muscle-Invasive Bladder Cancer, BMS-986205
  • Intervention: Biological: Nivolumab, Drug: BMS-986205, Drug: Gemcitabine, Drug: Cisplatin, Drug: BMS-986205 Placebo
  • Study ID: NCT03661320
View Trial

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

  • Condition: Acinar Cell Carcinoma, Adrenal Cortex Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Appendix Mucinous Adenocarcinoma, Bladder Adenocarcinoma, Bronchioloalveolar Carcinoma, Ce
  • Intervention: Procedure: Biospecimen Collection, Biological: Ipilimumab, Biological: Nivolumab
  • Study ID: NCT02834013
View Trial

Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Radiation: Radiation Therapy
  • Study ID: NCT03486197
View Trial

A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

  • Condition: Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, PD-L1 Positive, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder
  • Intervention: Biological: Pembrolizumab, Drug: Tazemetostat
  • Study ID: NCT03854474
View Trial

A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics

  • Condition: Bladder Cancer
  • Intervention: Drug: Abemaciclib
  • Study ID: NCT03837821
View Trial

A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

  • Condition: Urinary Bladder Cancer, Invasive Bladder Cancer
  • Intervention: Combination Product: nivolumab 480mg, Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg, Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg
  • Study ID: NCT03844256
View Trial

A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

  • Condition: Bladder Cancer, Urothelial Carcinoma
  • Intervention: Drug: 18F-fluciclovine, Device: PET/CT
  • Study ID: NCT04018053
View Trial

A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Durvalumab
  • Study ID: NCT03768570
View Trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEY

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Pembrolizumab, Radiation: Conventional Radiotherapy (Bladder only), Radiation: Conventional Radiotherapy (Bladder and pelvic nodes), Radiation: Hypofractionated Radiotherapy (Bladder only), Drug: Cisplatin, Drug: Fluorouracil (5-FU), Drug: Mitomycin C (MMC), Drug: Gemcitabine, Drug: Placebo to Pembrolizumab
  • Study ID: NCT04241185
View Trial

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

  • Condition: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
  • Intervention: Drug: Infigratinib, Drug: Placebo
  • Study ID: NCT04197986
View Trial

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

  • Condition: Urothelial Cancer
  • Intervention: Drug: Enfortumab vedotin, Drug: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine
  • Study ID: NCT04223856
View Trial

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

  • Condition: Urothelial Carcinoma, Bladder Cancer, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Cancer, Transitional Cell Carcinoma
  • Study ID: NCT04527991
View Trial

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

  • Condition: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
  • Study ID: NCT04579380
View Trial

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

  • Condition: Muscle Invasive Bladder Cancer
  • Study ID: NCT04700124
View Trial

A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

  • Condition: Renal Pelvis and Ureter Urothelial Carcinoma
  • Study ID: NCT04628767
View Trial